Search results
Novavax (NVAX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Zacks via Yahoo Finance· 18 hours agoNovavax (NVAX) possesses the right combination of the two key ingredients for a likely earnings beat...
Novavax (NVAX) Q4 Earnings & Sales Miss Estimates, Stock Tanks
Zacks via Yahoo Finance· 2 months agoNovavax, Inc. NVAX reported a fourth-quarter 2023 loss of $1.44 cents per share, much wider than the...
Is Novavax Stock A Buy After Winning A Key Designation From The World Health Organization?
Investor's Business Daily· 3 months agoNovavax stock remained bound under its key moving averages in January 2024 despite winning numerous...
Novavax, Inc. (NASDAQ:NVAX) Shares Fly 54% But Investors Aren't Buying For Growth
Simply Wall St. via Yahoo Finance· 1 year agoNovavax, Inc. (NASDAQ:NVAX) shareholders are no doubt pleased to see that the share price has...
This Just In: Analysts Are Boosting Their Novavax, Inc. (NASDAQ:NVAX) Outlook for This Year
Simply Wall St. via Yahoo Finance· 12 months agoShareholders in Novavax, Inc. (NASDAQ:NVAX) may be thrilled to learn that the analysts have just...
Novavax Plummets On Downgrade: Is It The Covid Engine That Couldn't?
Investor's Business Daily· 1 year agoNovavax has a solid platform but continues to face a $700 million litigation headwind, an analyst...
Novavax (NVAX) Q3 Earnings Miss, Lowers '22 Sales Outlook
Zacks via Yahoo Finance· 1 year agoNovavax, Inc. NVAX incurred a loss of $2.15 per share for third-quarter 2022, which missed the Zacks...
Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know
Zacks via Yahoo Finance· 2 years agoNovavax (NVAX) closed at $51.67 in the latest trading session, marking a -0.27% move from the prior...
Why Wall Street Thinks Novavax Is a No-Brainer Stock to Buy Right Now
Motley Fool· 2 years agoNovavax (NASDAQ: NVAX) is very late to the party in entering the COVID-19 vaccine market. Wall...
Novavax Outlook: Why NVAX Stock Could 12X in the Next 12 Months
InvestorPlace via Yahoo Finance· 1 year agoAfter recently reporting strong clinical data, Novavax (NASDAQ:NVAX) has tremendous opportunities in front of it. More specifically, the company’s coronavirus booster and its coronavirus-flu ...